Dr. Javid Moslehi, M.D., is one of the members of the Myocarditis Foundation’s Medical Advisory Board. Dr. Moslehi and his team have reasoned that using a novel class of therapies called JAK inhibitors would be a possible treatment modality for acute fulminant myocarditis. In recent years, the team has examined the effects of JAK inhibitor treatment on the immune cell populations for both RNA and proteins, showing acute benefit in various laboratory models of myocarditis.
Please read the two articles below about this wonderful finding. There will need to be a clinical trial to confirm the findings, but something to look forward to in the help for patients with Fulminant Myocarditis.
